( NASDAQ: MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year.
Zoci plus atezolizumab had an estimated 81.9% six-month rate without progression or death; Zai Lab expects to start a global ...
The zoldonrasib combination produced a 54% response rate in 35 evaluable pancreatic cancer patients. Tango expects to start a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results